IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer

Copenhagen, Denmark – September 27th, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, announces that the first patient has received the first dose in an international Phase I/II clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA® (pembrolizumab) for patients with non-small cell lung cancer (NSCLC) – NCT03562871.

“The enrolment of the first patient in our Phase I/II trial for NSCLC represents a major milestone for IO Biotech, and we are excited that our global trial is now active and recruiting patients. The first patient is now being treated in a first-line treatment setting of metastatic non-small cell lung cancer” said Eva Ehrnrooth, MD, PhD, Chief Medical Officer of IO Biotech. “Through this trial, we expect to get a diverse set of clinical data. This will enable us to explore the potential of IO102 when added to the current standard of care.”
IO Biotech’s lead candidate, IO102, is an IDO-derived immune modulating therapy with a dual mode of action – killing both cancer and immune-suppressive cells. IO Biotech’s IDO-derived immune modulating therapies have previously shown both a favorable safety profile and promising anti-tumor activity in a first-in man trial of heavily pre-treated patients with NSCLC.

The IO102-012/KN-764 trial is part of a collaborative agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada). The clinical trial will be sponsored by IO Biotech. IO Biotech has retained global commercial rights to IO102.
About the study IO102-012/KEYNOTE-764: An Open-label, Randomized, Phase 1/2 Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chemotherapy, as first-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer. This global clinical trial will accrue patients from more than 20 sites in the US and Europe.

The clinical trial will be sponsored by IO Biotech while MSD will supply the trial with KEYTRUDA. The rights to the study results will be shared. IO Biotech will maintain global commercial rights to IO102.
About IO Biotech IO Biotech is a clinical stage biotech company developing disruptive immune therapies for treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-Win, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.
About T-win technology platform IO Biotech’s proprietary T-win technology platform enables identification of compounds with dual mechanism of action targeting and directly killing immunosuppressive cells and tumor cells, and indirectly activation of other T-effectors, leading to strong anti-tumor responses.

For further information, please visit: www.iobiotech.com.

About NSCLC Lung cancer, which forms in the tissues of the lungs, usually within cells lining the air passages, is the leading cause of cancer death worldwide. Each year, more people die of lung cancer than colon, breast and prostate cancers combined. The two main types of lung cancer are non-small cell and small cell. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all cases. The five-year survival rate for patients suffering from highly advanced, metastatic (Stage IV) lung cancers is estimated to be 2 percent.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Contacts Mai-Britt Zocca, PhD, CEO and founder of IO Biotech
E-mail: mz@iobiotech.com


90 million to 18 Talented Researchers
19. October 2020
Søren Dinesen Lumdbeckfonden
Psychiatry research leads to prestigious science prize
13. October 2020
Christian Sandøe Musaeus Lundbeckfonden
Concentrating on Dementia
13. October 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge